Omalizumab In The Treatment Of Refractory Urticarial Vasculitis Triggered By SARS-Cov-2 Infection: A Pediatric Case Report

Omalizumab In The Treatment Of Refractory Urticarial Vasculitis Triggered By SARS-Cov-2 Infection: A Pediatric Case Report

Authors

  • Yusuf Can Edek Gazi University Faculty of Medicine
  • Ecem Ertürk Gazi University Faculty of Medicine
  • Esra Adışen Gazi University Faculty of Medicine

Keywords:

COVID-19, omalizumab, urticarial vasculitis

References

Marzano AV, Maronese CA, Genovese G, et al. Urticarial vasculitis: Clinical and laboratory findings with a particular emphasis on differential diagnosis. J Allergy Clin Immunol. 2022;149(4):1137-1149. DOI:10.1016/j.jaci.2022.02.007

Kolkhir P, Grakhova M, Bonnekoh H, Krause K, Maurer M. Treatment of urticarial vasculitis: A systematic review. J Allergy Clin Immunol. 2019;143(2):458-466. DOI:10.1016/j.jaci.2018.09.007

de Perosanz-Lobo D, Fernandez-Nieto D, Burgos-Blasco P, et al. Urticarial vasculitis in COVID-19 infection: a vasculopathy-related symptom? J Eur Acad Dermatol Venereol. 2020;34(10):e566-e568. DOI:10.1111/jdv.16713

Wang S, Fu L, Xiang X, Zhang B, Ma L, Xing H. Successful treatment of urticarial vasculitis with omalizumab in children: a case series. Clin Exp Dermatol. 2023;48(10):1145-1148. DOI:10.1093/ced/llad192

Petrelli F, Giannini D, Bilia S, et al. Efficacy and safety of omalizumab therapy in urticaria vasculitis. Front Allergy. 2022;3:952079. DOI:10.3389/falgy.2022.952079

Downloads

Published

2024-10-30

How to Cite

1.
Omalizumab In The Treatment Of Refractory Urticarial Vasculitis Triggered By SARS-Cov-2 Infection: A Pediatric Case Report. Dermatol Pract Concept [Internet]. 2024 Oct. 30 [cited 2024 Nov. 7];14(4):e2024252. Available from: https://dpcj.org/index.php/dpc/article/view/4512

Share